Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women - PREFER a randomized, placebo-controlled study

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Favrat, Bernard ^a   Balck, Katharina ^b   Breymann, Christian ^c   Hedenus, Michael ^d   Keller, Thomas ^e   Mezzacasa, Anna ^f   Gasche, Christoph ^g  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Private Practice for Internal Medicine   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d SUNDSVALL HOSPITAL   (Sweden)

^e Acomed Statistics   (Germany)

^f Vifor (International) Inc   (Switzerland)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; PLACEBO; SODIUM CHLORIDE; FERRIC ION; IRON; MALTOSE; TRANSFERRIN;

ADULT; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; ASYMPTOMATIC DISEASE; AUSTRIA; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ERYTHROPOIESIS; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GERMANY; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE DISCOLORATION; IRON DEFICIENCY; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NIGHT SWEAT; PHOSPHATE BLOOD LEVEL; PIPER FATIGUE SCALE; PREMATURITY; PREMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHORT FORM 12; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SWEDEN; SWITZERLAND; THORAX PAIN; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; BIOASSAY; BLOOD; DEFICIENCY; DOSE RESPONSE; INTENTION TO TREAT ANALYSIS; MEAN CORPUSCULAR VOLUME; METABOLISM; PATHOPHYSIOLOGY;

ADULT; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; ERYTHROCYTE INDICES; FATIGUE; FEMALE; FERRIC COMPOUNDS; HEMOGLOBINS; HUMANS; INTENTION TO TREAT ANALYSIS; IRON; MALTOSE; PLACEBOS; QUALITY OF LIFE; TRANSFERRIN;

EID: 84899667132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094217     Document Type: Article

References (48)

1. Bates DW, Schmitt W, Buchwald D, Ware NC, Lee J, et al. (1993) Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med 153: 2759-2765. (Pubitemid 24005651)
2. Pawlikowska T, Chalder T, Hirsch SR, Wallace P, Wright DJ, et al. (1994) Population based study of fatigue and psychological distress. BMJ 308: 763-766. (Pubitemid 24087440)
3. Cullen W, Kearney Y, Bury G (2002) Prevalence of fatigue in general practice. Ir J Med Sci 171: 10-12.
4. Brownlie T, Utermohlen V, Hinton PS, Haas JD (2004) Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 79: 437-443. (Pubitemid 41115588)
5. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G (2011) Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 118: 3222-3227.
6. Murray-Kolb LE, Beard JL (2007) Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 85: 778-787. (Pubitemid 46393510)
7. Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, et al. (2003) Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 326: 1124.
8. Vaucher P, Druais PL, Waldvogel S, Favrat B (2012) Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ 184: 1247-1254.
9. Murray CJ, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369: 448-457.
10. Evstatiev R, Gasche C (2012) Iron sensing and signalling. Gut 61: 933-952.
11. Brownlie T, Utermohlen V, Hinton PS, Giordano C, Haas JD (2002) Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr 75: 734-742. (Pubitemid 34256352)
12. von Drygalski A, Adamson JW (2011) Ironing out fatigue. Blood 118: 3191-3192.
13. WHO (2001) Iron Deficiency Anaemia - Assessment, Prevention, and Control. A guide for programme managers (WHO/NHD/01.3). Available: http://www.who.int/ nutrition/publications/micronutrients/anaemia-iron-deficiency/WHO-NHD-01.3/en/ index.html. Accessed 29 June 2013.
14. Galan P, Yoon HC, Preziosi P, Viteri F, Valeix P, et al. (1998) Determining factors in the iron status of adult women in the SU.VI.MAX study. SUpplementation en VItamines et Mineraux AntioXydants. Eur J Clin Nutr 52: 383-388. (Pubitemid 28284775)
15. Hercberg S, Preziosi P, Galan P (2001) Iron deficiency in Europe. Public Health Nutr 4: 537-545. (Pubitemid 32524575)
16. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, et al. (1998) The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25: 677-684.
17. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. Ann Oncol 23: 1954-1962.
18. Breymann C, Honegger C, Holzgreve W, Surbek D (2010) Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet : 577-580.
19. Pavord S, Myers B, Robinson S, Allard S, Strong J, et al. (2012) UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol 156: 588-600.
20. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1 Suppl 1: S4-S8.
21. SF-36.org (2000) The SF-12®: An Even Shorter Health Survey. Available: http://www.sf-36.org/tools/sf12.shtml. Accessed 29 June 2013.
22. United BioSource Corporation (2012) Computerized Cognitive Testing.
23. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J med Psychol 47: 211-218.
24. Beutler E, Larsh SE, Gurney CW (1960) Iron therapy in chronically fatigued, nonanemic women: a double-blind study. Ann Intern Med 52: 378-394.
25. Qunibi WY (2010) The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 60: 399-412.
26. Cho MH, Dodd MJ, Cooper BA, Miaskowski C (2012) Comparisons of exercise dose and symptom severity between exercisers and nonexercisers in women during and after cancer treatment. J Pain Symptom Manage 43: 842-854.
27. Cuijpers P, van SA, van SA, Andersson G (2009) Psychological treatment of depression in primary care: a meta-analysis. Br J Gen Pract 59: e51-e60.
28. Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, et al. (2007) User's manual for the SF-36v2© Health Survey. 2nd ed. Lincoln,RI: QualityMetric Inc.
29. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655. (Pubitemid 13149996)
30. Duyn JH (2011) High-field MRI of brain iron. Methods Mol Biol 711: 239-249.
31. (1999) An evidence-based guideline for the management of heavy menstrual bleeding. Working Party for Guidelines for the Management of Heavy Menstrual Bleeding. N Z Med J 112: 174-177.
32. Provan D (2005) Oxford Handbook of Clinical and Laboratory Investigation. 2 ed. Oxford, New York: Oxford University Press.
33. Boon NA, Colledge NR, Walker BR (2006) Davidson's Principles & Practice of Medicine. Edinburgh: Elsevier.1023-30 p.
34. Anker SD, Comin CJ, Filippatos G, Willenheimer R, Dickstein K, et al. (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361: 2436-2448.
35. Breymann C, Gliga F, Bejenariu C, Strizhova N (2008) Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 101: 67-73.
36. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, et al. (2008) Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 199: 435-437.
37. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, et al. (2011) FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Gastroenterology 141: 846-853.
38. WHO (2000) Safety monitoring of medicinal products: Guidelines for setting up and running a pharmacovigilance centre. Available: http://apps.who.int/medicinedocs/en/d/Jh2934e/15.html. Accessed 29 June 2013.
39. Weiss G (2002) Iron and immunity: a double-edged sword. Eur J Clin Invest 32 Suppl 1: 70-78.
40. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A (2007) Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 110: 267-278. (Pubitemid 47356650)
41. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, et al. (2009) Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 49: 2719-2728.
42. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, et al. (2011) A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 26: 1599-1607.
43. Munoz M, Martin-Montanez E (2012) Ferric carboxymaltose for the treatment of iron-deficiency anemia. [corrected]. Expert Opin Pharmacother 13: 907-921.
44. European Medicines Agency (2013) Assessment report for: Iron containing intravenous (IV) medicinal products. Available: http://www.ema.europa.eu/docs/ en-GB/document-library/Referrals-document/IV-iron-31/WC500150771.pdf.
45. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, et al. (2008) A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 103: 1182-1192. (Pubitemid 351677967)
46. Buynak R, Shapiro DY, Okamoto A, Van H, I, Rauschkolb C, et al. (2010) Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 11: 1787-1804.
47. Vits S, Cesko E, Benson S, Rueckert A, Hillen U, et al. (2013) Cognitive factors mediate placebo responses in patients with house dust mite allergy. PLoS One 8: e79576.
48. Szucs TD, Blank P, Schwenkglenks M, Aapro M (2011) Potential health economic impact of i.v. iron supplementation to ESA treatment in patients with cancer- or chemotherapy-induced anaemia. Oncology 81: 45-49.